Download PDF
Semin Liver Dis 2004; 24: 61-68
DOI: 10.1055/s-2004-832930
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Hepatitis C Virus in the Setting of HIV or Hepatitis B Virus Coinfection

Richard K. Sterling1 , Mark S. Sulkowski2
  • 1Virginia Commonwealth University Health System/Medical College of Virginia, Richmond, Virginia
  • 2Johns Hopkins University School of Medicine, Baltimore, Maryland
Further Information

Publication History

Publication Date:
02 September 2004 (online)

    Permissions and Reprints

Because of shared routes of transmission, coinfection with hepatitis C virus (HCV) or hepatitis B virus (HBV), or both, is common among HIV-infected persons, affecting approximately 15 to 30% and 10 to 15% of patients, respectively. Advances in antiretroviral therapy have improved the life expectancy of patients infected with HIV, and, as a consequence, HCV-related liver disease has emerged as a significant comorbid disease among such patients. Concurrent HIV infection may be associated with higher serum HCV RNA levels, accelerated progression of hepatic fibrosis, increased risk of end-stage liver disease, hepatocellular carcinoma and death among persons coinfected with hepatitis C. Similarly, coinfection with HCV and HBV may lead to more severe liver disease and greater risk of hepatocellular carcinoma (HCC) than does HCV infection alone. Although definitive randomized controlled trials are not yet completed, current guidelines recommend the use of pegylated interferon alfa plus ribavirin for the treatment of chronic HCV in eligible HIV-infected persons. Conversely, the optimal treatment of chronic HCV in persons with chronic HBV infection has not been defined but may include pegylated interferon alfa plus ribavirin, with or without additional antiviral agents, such as lamivudine or adefovir, or both.

KEYWORDS

HCV-HIV - HCV-HBV coinfection

REFERENCES

  • 1 Sherman K E, Rouster S D, Chung R T, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.  Clin Infect Dis. 2002;  34 831-837
    CrossrefPubMedGoogle Scholar
  • 2 Sulkowski M S, Brinkley-Laughton S, Thomas D L. HCV and HIV co-infection: prevalence, genotype distribution and severity of liver disease in an urban HIV clinic.  Hepatology. 2000;  32 212
    PubMedGoogle Scholar
  • 3 Zarski J-P, Bohn B, Bastie A. Characteristics of patients with dual infection by hepatitis B and C viruses.  J Hepatol. 1998;  28 27-33
    CrossrefPubMedGoogle Scholar
  • 4 Lee L M, Karon J M, Selik R et al.. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997.  JAMA. 2001;  285 1308-1315
    CrossrefPubMedGoogle Scholar
  • 5 Palella Jr F J, Delaney K M, Moorman A C et al.. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.  N Engl J Med. 1998;  338 853-860
    CrossrefPubMedGoogle Scholar
  • 6 Graham C S, Baden L R, Yu E et al.. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.  Clin Infect Dis. 2001;  33 562-569
    CrossrefPubMedGoogle Scholar
  • 7 Bica I, McGovern B, Dhar R et al.. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.  Clin Infect Dis. 2001;  32 492-497
    PubMedGoogle Scholar
  • 8 Greub G, Ledergerber B, Battegay M et al.. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.  Lancet. 2000;  356 1800-1805
    CrossrefPubMedGoogle Scholar
  • 9 Daar E S, Lynn H, Donfield S et al.. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs.  J Infect Dis. 2001;  183 589-595
    CrossrefPubMedGoogle Scholar
  • 10 Dorrucci M, Pezzotti P, Phillips A N et al.. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study.  J Infect Dis. 1995;  172 1503-1508
    PubMedGoogle Scholar
  • 11 Sulkowski M S, Moore R D, Mehta S H et al.. Hepatitis C and progression of HIV disease.  JAMA. 2002;  288 199-206
    CrossrefPubMedGoogle Scholar
  • 12 Eyster M E, Fried M W, Di Bisceglie A M, Goedert J J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease.  Blood. 1994;  84 1020-1023
    PubMedGoogle Scholar
  • 13 Bonacini M, Govindarajan S, Blatt L M et al.. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA.  J Viral Hepat. 1999;  6 203-208
    PubMedGoogle Scholar
  • 14 Soto B, Sanchez-Quijano A, Rodrigo L et al.. Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis.  J Hepatol. 1997;  26 1-5
    PubMedGoogle Scholar
  • 15 Puoti M, Bonacini M, Spinetti A et al.. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus.  J Infect Dis. 2001;  183 134-137
    CrossrefPubMedGoogle Scholar
  • 16 Allory Y, Charlotte F, Benhamou Y et al.. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group.  Hum Pathol. 2000;  31 69-74
    PubMedGoogle Scholar
  • 17 Benhamou Y, Bochet M, Di Martino V et al.. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.  Hepatology. 1999;  30 1054-1058
    CrossrefPubMedGoogle Scholar
  • 18 Benhamou Y, Di M V, Bochet M et al.. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.  Hepatology. 2001;  34 283-287
    CrossrefPubMedGoogle Scholar
  • 19 Garcia-Samaniego J, Soriano V, Castilla J et al.. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C.  Am J Gastroenterol. 1997;  92 1130-1134
    PubMedGoogle Scholar
  • 20 Sterling R K, Contos M J, Sanyal A J et al.. The clinical spectrum of hepatitis C virus in HIV coinfection.  J Acquir Immune Defic Syndr. 2003;  32 30-37
    CrossrefPubMedGoogle Scholar
  • 21 Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus.  Clin Infect Dis. 2001;  33 1793-1795
    CrossrefPubMedGoogle Scholar
  • 22 Ragni M V, Belle S H. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection.  J Infect Dis. 2001;  183 1112-1115
    CrossrefPubMedGoogle Scholar
  • 23 Torre D, Tambini R, Cadario F et al.. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy.  Clin Infect Dis. 2001;  33 1579-1585
    CrossrefPubMedGoogle Scholar
  • 24 National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C . 2002;  , available at: http://consensus.nih.gov/cons/116/116cdc_intro.htm
  • 25 Soriano V, Garcia-Samaniego J, Bravo R. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus.  Clin Infect Dis. 1996;  23 585-591
    PubMedGoogle Scholar
  • 26 Landau A, Batisse D, Piketty C et al.. Long-term efficacy of combination therapy with interferon alpha-2b and ribavirin for severe chronic hepatitis C in HIV-infected patients.  AIDS. 2001;  15 2149-2155
    CrossrefPubMedGoogle Scholar
  • 27 Sauleda S, Juarez A, Esteban J I et al.. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.  Hepatology. 2001;  34 1035-1040
    CrossrefPubMedGoogle Scholar
  • 28 Kostman J R, Smith J J, Giffen C, Frost K R. Interferon alpha-2B/ribavirin combination therapy in HIV/HCV co-infected persons: results of a multicenter randomized, double-blind, controlled trial.  Hepatology. 2001;  34 330
    PubMedGoogle Scholar
  • 29 Chung R, Anderson J, Alston B et al.. A randomized, controlled trial of pegylated interferon alpha-2a with ribavirin vs. interferon alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections February 24-28, 2002 Seattle, WA;
    Google Scholar
  • 30 Hoggard P G, Kewn S, Barry M G et al.. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro.  Antimicrob Agents Chemother. 1997;  41 1231-1236
    PubMedGoogle Scholar
  • 31 Vogt M W, Hartshorn K L, Furman P A et al.. Ribavirin antagonizes the effect of azidothymidine on HIV replication.  Science. 1987;  235 1376-1379
    PubMedGoogle Scholar
  • 32 Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.  Lancet. 2001;  357 280-281
    CrossrefPubMedGoogle Scholar
  • 33 Landau A O, Batisse D P, Van Huen J PD et al.. Efficacy and safety of combination therapy with interferon-alpha-2b and ribavirin for chronic hepatitis C in HIV-infected patients.  AIDS. 2000;  14 839-844
    PubMedGoogle Scholar
  • 34 Zylberberg H, Benhamou Y, Lagneaus J L et al.. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.  Gut. 2000;  47 694-697
    CrossrefPubMedGoogle Scholar
  • 35 Mohamed A E, Ven D, Al Karawi M A. Dual infection with hepatitis C and B viruses: clinical and histologic study in Saudi patients.  Hepatogastroenterology. 1997;  44 1404-1406
    PubMedGoogle Scholar
  • 36 Alberti A, Pontisso P, Chemello L. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease.  J Hepatol. 1995;  22 38-41
    PubMedGoogle Scholar
  • 37 Kew M C, Yu M C, Kedda M et al.. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks.  Gastroenterology. 1997;  112 184-187
    PubMedGoogle Scholar
  • 38 Fukuda R, Ishimura N, Niigaki M et al.. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance.  J Med Virol. 1999;  58 201-207
    CrossrefPubMedGoogle Scholar
  • 39 Sagnelli E, Copolla N, Colastico C et al.. HCV genotype and ‘silent’ HBV infection: two main risk factors for a more severe liver disease.  J Med Virol. 2001;  64 350-355
    CrossrefPubMedGoogle Scholar
  • 40 Cacciola I, Pollicino T, Squadrito G et al.. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.  N Engl J Med. 1999;  341 22-26
    CrossrefPubMedGoogle Scholar
  • 41 Thomas D L, Astemborski J, Rai R M et al.. The natural history of hepatitis C virus infection: host, viral, and environmental factors.  JAMA. 2000;  284 450-456
    CrossrefPubMedGoogle Scholar
  • 42 Wang Y M, Ng W C, Lo S K. Suppression of hepatitis C virus by hepatitis B virus in coinfected patients at the National University Hospital of Singapore.  J Gastroenterol. 1999;  34 481-485
    CrossrefPubMedGoogle Scholar
  • 43 Weltman M D, Brotodihardjo A, Crewe E B et al.. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment.  J Viral Hepat. 1995;  2 39-45
    PubMedGoogle Scholar
  • 44 Villa E, Grottola A, Buttafoco P et al.. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.  Am J Gastroenterol. 2001;  96 2973-2977
    PubMedGoogle Scholar
  • 45 Zignego A L, Fontana R, Puliti S et al.. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C coinfection.  Arch Virol. 1997;  142 535-544
    CrossrefPubMedGoogle Scholar
  • 46 Cooksley W GE, Piratvisuth T, Wang Y-J et al.. 40 Kda peginterferon alfa-2a (Pegasys): efficacy and safety results from a phase II, randomized, actively controlled, multicenter study in the treatment of HBVEAG positive chronic hepatitis B.  Hepatology. 2001;  34 349A
    PubMedGoogle Scholar
  • 47 Nunez M, Lana R, Mendoza J L et al.. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.  J Acquir Immune Defic Syndr. 2001;  27 426-431
    PubMedGoogle Scholar
  • 48 Mauss S, Klinker H, Ulmer A et al.. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count.  Infection. 1998;  26 16-19
    PubMedGoogle Scholar
  • 49 Rodriguez-Torres M. Interferon alfacon-1 (Infergen) treatment for prior interferon alfa-2a or 2b non-responders coinfected with hepatitis C virus and HIV.  Hepatology. 1999;  30 626A
    PubMedGoogle Scholar
  • 50 Causse X, Payen J, Izopet J et al.. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment?.  J Hepatol. 2000;  32 1003-1010
    CrossrefPubMedGoogle Scholar
  • 51 Prestileo T, Mazzola G, Di Lorenzo F. Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients.  Int J Antimicrob Agents. 2000;  16 373-378
    PubMedGoogle Scholar
  • 52 Bruno R, Sacchi P, Filice C, Filice G. Aggressive daily interferon therapy in HIV-HCV coinfected patients.  J Acquir Immune Defic Syndr. 2000;  25 372-373
    PubMedGoogle Scholar
  • 53 Morsica G, De Bona A, Foppa C U et al.. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment.  AIDS. 2000;  14 1656-1658
    PubMedGoogle Scholar
  • 54 Suciu L, Goldman D J, Jones J et al.. Sustained virologic response following interferon and ribavirin therapy for hepatitis C patients who are co-infected with HIV. 38th meeting of the Infectious Disease Society of America Seattle, WA; September 7-10, 2000: 234. (Abst)
    Google Scholar
  • 55 Landau A, Batisse D, Piketty C et al.. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy.  AIDS. 2000;  14 1857-1858
    PubMedGoogle Scholar
  • 56 Perez-Olmeda M, Asensi V, Romero M. Treatment of chronic hepatitis C: SHIRT (Spanish HIV Interferon Ribavirin Trial). Presented at the Ninth Conference on Retroviruses and Opportunistic Infections February 24-28, 2002 Seattle, WA;
    Google Scholar
  • 57 Nasti G, Di Gennaro G, Tavio M et al.. Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon alfa-2b and ribavirin combination therapy.  J Acquir Immune Defic Syndr. 2001;  26 299-300
    PubMedGoogle Scholar
  • 58 Bochet M, De Torres M A, Valantin V et al.. Efficacy and tolerance of IFN-alpha plus ribavirin for chronic hepatitis C in HIV-infected patients. Presented at the Eighth Conference on Retroviruses and Opportunistic Infections February 4-8, 2001 Chicago, IL;
    Google Scholar

Richard K SterlingM.D. 

Virginia Commonwealth University Health System/Medical College of Virginia

Box 980341, 1200 East Broad Street, Room 1492

Richmond, VA 23298

Email: rksterli@hsc.vcu.edu

      >